A Phase 3 interventional study of Methotrexate and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 42nd largest by enrollment, is one of 5 that started in 2006, is one of 47 in phase 3, and was the 22nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 48th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 35th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents. Patients will receive MabThera (1g i.v.) on days 1 and 15, concomitantly with methotrexate >=15mg p.o./week. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
Drug: Methotrexate · Drug: rituximab [MabThera/Rituxan]
\>=15 mg po/week
Drug page: Rituximab
1g iv on days 1 and 15
Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death
An Adverse event (AE) was considered any unfavorable medical event in a participant of clinical research who received the study drug and that not necessarily had a causal relationship with this treatment. An AE could, therefore, being any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A serious adverse event (SAE) is any experience that suggested a significant risk, contraindication, caution, and at any dose fulfills at least one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment.
Time frame: Up to Week 48
Number of Participants With AEs According to Degree of Intensity
An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. The Intensity of AEs was classified as Grade 1, Grade 2, Grade 3 and Grade 4. Grade 1: Discomfort was noticed, but the normal daily activity was not interrupted. Grade 2: Discomfort was enough to reduce the normal daily activity. Grade 3: There was disability for work or develop normal daily activities. Grade 4: It represented an immediate threat to life (these events were reported as SAEs).
Time frame: Up to Week 48
Number of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs
An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A SAE is any experience that suggested a significant risk, contraindication, caution, and at any dose, fulfills, at least, one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment. Relationship between AEs and medication under investigation was evaluated through the classification "Yes" and "No". A relationship classified as "Yes" implied a significant causal relationship with the medication under investigation which was evaluated based on enough evidences, facts or arguments.
Time frame: Up to Week 48
Number of Participants With AEs of Special Interest During the Study
Adverse event of special interest during the study treatment and follow up period included infections. The participants with AEs of special interest were reported at Screening, End of treatment (EOT), and End of Follow-up (EOFU) visit.
Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Mean Values of Hematology Parameters at Screening and EOT Visit (Hemoglobin and Mean Corpuscular Hemoglobin Concentration)
The values of hemoglobin (Hb) and mean corpuscular hemoglobin concentration (MCHC) for each participant were estimated at Screening and at EOT visit.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Hematology Parameters at Screening and EOT Visit (Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)
The hematology parameters (hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) for each participant were estimated at Screening and at EOT.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Hematology Parameter at Screening and EOT Visit (Mean Corpuscular Volume)
Mean corpuscular volume (MCV) is the average volume of red cells. The mean MCV concentration for each participant was estimated at Screening and EOT.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Hematology Parameter at Screening and EOT Visit (Erythrocytes)
The mean erythrocyte concentration for each participant was estimated at Screening and at EOT.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Hematology Parameters at Screening and EOT Visit (Leucocytes and Platelets)
The mean leucocytes and platelets concentration for each participant was estimated at Screening, at EOT visit.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Biochemistry Parameters at Screening and Visit 8 (Albumin and Glucose)
The mean albumin and glucose concentration for each participant was estimated at Screening and at EOT visit.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Cholesterol, Uric Acid, Urea, Creatinine, Calcium, Total Bilirubin and Serum Total Proteins at Screening and EOT Visit.
The mean concentration of cholesterol, uric acid, urea, creatinine, calcium, total bilirubin and serum total proteins (STP) for each participant was estimated at Screening and at EOT visit.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Potassium, Chlorine, Sodium, and Phosphorus at Screening and EOT Visit
The mean concentration of potassium, chlorine, sodium and phosphorus for each participant was estimated at Screening and at EOT.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Values of Aspartate Transaminase, Alanine Transaminase, Alkaline Phosphatase, and Lactic Dehydrogenase at Screening and EOT Visit
The mean aspartate transaminase (AST) and alanine transaminase (ALT), Alkaline phosphatase (AP), and Lactic dehydrogenase (LDH) concentration for each participant was estimated at Screening and at EOT visit.
Time frame: Screening (Days -28 to 0) and EOT (Week 24)
Mean Duration of Morning Joint Stiffness
The efficacy of rituximab was assessed by evaluating mean duration of morning joint stiffness.
Time frame: Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Mean Value of Painful Joints
The efficacy of rituximab was assessed by evaluating painful joints.
Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Number of Participants With American College of Rheumatology (20, 50, and 70) Criteria
American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender joints and swollen joints, as well as for three of the additional five ACR core set variables: patient's assessment of pain using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain); patient's global assessment of disease activity and physician's global assessment of disease activity using a VAS (0=no disease activity to 100=maximum disease activity); health assessment questionnaire (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant; C-reactive protein and globular sedimentation velocity.
Time frame: Week 1, Week 12, and Week 24
Mean Value of Quality of Life (Health Assessment Questionnaire - Disease Index)
Health Assessment Questionnaire - Disease Index (HAQ-DI) indicates how the disease affected participant's activities of daily life. It consisted of 20 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale, 0=without any difficulty to 3=unable to do. Sum of scores was divided by number of domains with a score for a total possible score of 0 (best/no difficulties to perform activities) to 3 (worst/ unable to perform activities at all).
Time frame: Screening (Days -28 to 0), Week 1, Week 12, and Week 24
Mean Values of C Reactive Protein
C Reactive Protein (CRP) is a component of ACR. CRP is a marker of inflammation.
Time frame: Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Mean Values of Globular Sedimentation Velocity
Globular sedimentation velocity is a component of ACR.
Time frame: Screening ((Days -28 to 0), Week 1, Week 12, and Week 24
Mean Values of Pain and Activity Based on Visual Analogue Scale
Pain assessment was assessed by using a VAS (0=no pain to 100=unbearable pain). Disease activity was also evaluated by participants and investigators by using a VAS (0=no disease activity to 100=maximum disease activity).
Time frame: Screening ((Days -28 to 0), Week 1, Week 12, and Week 24
Mean Value of Inflamed Joints
The efficacy of rituximab was assessed by evaluating inflamed joints.
Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
A total of 246 participants were enrolled in study conducted from 20 February 2006 to 05 December 2008 across 56 study centers in 10 Latin American countries.
| Milestone | Rituximab |
|---|---|
| Started | 232 |
| Completed | 188 |
| Not completed | 44 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Treatment failure | 25 |
| Withdrew: Withdrawal informed consent | 6 |
| Withdrew: Adverse event | 2 |
An Adverse event (AE) was considered any unfavorable medical event in a participant of clinical research who received the study drug and that not necessarily had a causal relationship with this treatment. An AE could, therefore, being any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A serious adverse event (SAE) is any experience that suggested a significant risk, contraindication, caution, and at any dose fulfills at least one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment.
| participants | Rituximab |
|---|---|
| Any AE | 189 |
| Any SAE | 12 |
| Death | 0 |
An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. The Intensity of AEs was classified as Grade 1, Grade 2, Grade 3 and Grade 4. Grade 1: Discomfort was noticed, but the normal daily activity was not interrupted. Grade 2: Discomfort was enough to reduce the normal daily activity. Grade 3: There was disability for work or develop normal daily activities. Grade 4: It represented an immediate threat to life (these events were reported as SAEs).
| participants | Rituximab |
|---|---|
| Grade 1 AEs | 170 |
| Grade 2 AEs | 102 |
| Grade 3 AEs | 30 |
| Grade 4 AEs | 12 |
An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A SAE is any experience that suggested a significant risk, contraindication, caution, and at any dose, fulfills, at least, one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment. Relationship between AEs and medication under investigation was evaluated through the classification "Yes" and "No". A relationship classified as "Yes" implied a significant causal relationship with the medication under investigation which was evaluated based on enough evidences, facts or arguments.
| participants | Rituximab |
|---|---|
| Any drug related AE | 97 |
| Any drug related SAE | 0 |
| Any AE leading to discontinuation | 2 |
Adverse event of special interest during the study treatment and follow up period included infections. The participants with AEs of special interest were reported at Screening, End of treatment (EOT), and End of Follow-up (EOFU) visit.
| participants | Rituximab |
|---|---|
| Screening | 5 |
| EOT | 12 |
| EOFU | 12 |
The values of hemoglobin (Hb) and mean corpuscular hemoglobin concentration (MCHC) for each participant were estimated at Screening and at EOT visit.
| g/deciliter (dL) | Rituximab |
|---|---|
| Hb, Screening | 12.4 ± 1.9 |
| Hb, EOT | 12.8 ± 1.6 |
| MCHC, Screening | 30.0 ± 3.6 |
| MCHC, EOT | 30.9 ± 2.7 |
The hematology parameters (hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) for each participant were estimated at Screening and at EOT.
| percentage of cells | Rituximab |
|---|---|
| Hematocrit, Screening | 37.8 ± 4.2 |
| Hematocrit, EOT | 38.9 ± 4.3 |
| Neutrophils, Screening | 67.8 ± 9.4 |
| Neutrophils, EOT | 65.1 ± 9.9 |
| Lymphocytes, Screening | 24.0 ± 7.7 |
| Lymphocytes, EOT | 25.6 ± 8.7 |
| Monocytes, Screening | 4.3 ± 3.1 |
| Monocytes, EOT | 5.4 ± 3.6 |
| Eosinophils, Screening | 1.9 ± 2.0 |
| Eosinophils, EOT | 2.5 ± 2.0 |
| Basophils, Screening | 0.2 ± 0.3 |
| Basophils, EOT | 0.3 ± 0.4 |
Mean corpuscular volume (MCV) is the average volume of red cells. The mean MCV concentration for each participant was estimated at Screening and EOT.
| femtoliters | Rituximab |
|---|---|
| MCV, Screening | 85.8 ± 8.5 |
| MCV, EOT | 87.7 ± 7.0 |
The mean erythrocyte concentration for each participant was estimated at Screening and at EOT.
| 10^12 cells/liter | Rituximab |
|---|---|
| Erythrocytes, Screening | 4.5 ± 1.2 |
| Erythrocytes, EOT | 4.4 ± 0.5 |
The mean leucocytes and platelets concentration for each participant was estimated at Screening, at EOT visit.
| 10^9 cells/liter | Rituximab |
|---|---|
| Leucocytes, Screening | 8.6 ± 2.6 |
| Leucocytes, EOT | 7.7 ± 2.3 |
| Platelets, Screening | 351.6 ± 112.5 |
| Platelets, EOT | 310.6 ± 97.1 |
The mean albumin and glucose concentration for each participant was estimated at Screening and at EOT visit.
| g/dL | Rituximab |
|---|---|
| Albumin, Screening | 3.9 ± 0.5 |
| Albumin, EOT | 4.1 ± 0.4 |
| Glucose, Screening | 86.1 ± 12.3 |
| Glucose, EOT | 88.1 ± 26.5 |
The mean concentration of cholesterol, uric acid, urea, creatinine, calcium, total bilirubin and serum total proteins (STP) for each participant was estimated at Screening and at EOT visit.
| mg/dL | Rituximab |
|---|---|
| Cholesterol, Screening | 187.9 ± 42.2 |
| Cholesterol, EOT | 196.6 ± 42.7 |
| Uric acid, Screening | 4.0 ± 1.2 |
| Uric acid, EOT | 4.0 ± 1.1 |
| Urea, Screening | 29.3 ± 10.0 |
| Urea, EOT | 30.2 ± 11.0 |
| Creatinine, Screening | 0.7 ± 0.2 |
| Creatinine, EOT | 0.7 ± 0.2 |
| Calcium, Screening | 9.0 ± 1.3 |
| Calcium, EOT | 9.0 ± 1.0 |
| Total Bilirubin, Screening | 0.7 ± 1.1 |
| Total Bilirubin, EOT | 0.7 ± 1.1 |
| STP, Screening | 7.3 ± 0.6 |
| STP, EOT | 7.1 ± 0.6 |
The mean concentration of potassium, chlorine, sodium and phosphorus for each participant was estimated at Screening and at EOT.
| millimoles per liter | Rituximab |
|---|---|
| Sodium, Screening | 140.1 ± 3.3 |
| Sodium, EOT | 140.4 ± 3.3 |
| Potassium, Screening | 4.2 ± 0.4 |
| Potassium, EOT | 4.2 ± 0.4 |
| Chlorine, Screening | 103.1 ± 4.2 |
| Chlorine, EOT | 103.3 ± 4.2 |
| Phosphorus, Screening | 3.7 ± 0.6 |
| Phosphorus, EOT | 3.8 ± 0.7 |
The mean aspartate transaminase (AST) and alanine transaminase (ALT), Alkaline phosphatase (AP), and Lactic dehydrogenase (LDH) concentration for each participant was estimated at Screening and at EOT visit.
| International units/liter | Rituximab |
|---|---|
| AST, Screening | 21.6 ± 9.7 |
| AST, EOT | 22.0 ± 9.5 |
| ALT, Screening | 24.1 ± 14.9 |
| ALT, EOT | 25.9 ± 14.9 |
| AP, Screening | 137.7 ± 71.6 |
| AP, EOT | 138.2 ± 81.7 |
| LDH, Screening | 311.0 ± 149.1 |
| LDH, EOT | 300.5 ± 125.4 |
The efficacy of rituximab was assessed by evaluating mean duration of morning joint stiffness.
| Minutes | Rituximab |
|---|---|
| Screening | 120.1 ± 96.3 |
| EOT | 16.0 ± 36.5 |
| EOFU | 19.9 ± 42.4 |
The efficacy of rituximab was assessed by evaluating painful joints.
| number of painful joints | Rituximab |
|---|---|
| Painful joints, Screening | 17.5 ± 8.6 |
| Painful joints, EOT | 3.8 ± 4.9 |
| Painful joints, EOFU | 4.4 ± 5.7 |
American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender joints and swollen joints, as well as for three of the additional five ACR core set variables: patient's assessment of pain using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain); patient's global assessment of disease activity and physician's global assessment of disease activity using a VAS (0=no disease activity to 100=maximum disease activity); health assessment questionnaire (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant; C-reactive protein and globular sedimentation velocity.
| participants | Rituximab |
|---|---|
| ACR 20, Week 1 | 1 |
| ACR 20, Week 12 | 84 |
| ACR 20, Week 24 | 88 |
| ACR 50, Week 1 | 0 |
| ACR 50, Week 12 | 50 |
| ACR 50, Week 24 | 62 |
| ACR 70, Week 1 | 0 |
| ACR 70, Week 12 | 33 |
| ACR 70, Week 24 | 42 |
Health Assessment Questionnaire - Disease Index (HAQ-DI) indicates how the disease affected participant's activities of daily life. It consisted of 20 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale, 0=without any difficulty to 3=unable to do. Sum of scores was divided by number of domains with a score for a total possible score of 0 (best/no difficulties to perform activities) to 3 (worst/ unable to perform activities at all).
| Scores on scale | Rituximab |
|---|---|
| Screening; n = 106 | 2.6 ± 1.3 |
| Week 1; n = 114 | 2.5 ± 1.4 |
| Week 12; n = 107 | 1.25 ± 1.0 |
| Week 24; n = 105 | 1.0 ± 1.0 |
C Reactive Protein (CRP) is a component of ACR. CRP is a marker of inflammation.
| milligrams per liter | Rituximab |
|---|---|
| Screening | 28.0 ± 45.3 |
| Week 1 | 27.6 ± 56.1 |
| Week 12 | 13.6 ± 25.0 |
| Week 24 | 15.3 ± 45.2 |
Globular sedimentation velocity is a component of ACR.
| millimeters per hour | Rituximab |
|---|---|
| Screening | 43.7 ± 22.8 |
| Week 1 | 41.1 ± 23.0 |
| Week 12 | 26.8 ± 17.8 |
| Week 24 | 24.6 ± 19.0 |
Pain assessment was assessed by using a VAS (0=no pain to 100=unbearable pain). Disease activity was also evaluated by participants and investigators by using a VAS (0=no disease activity to 100=maximum disease activity).
| Scores on scale | Rituximab |
|---|---|
| Pain, Screening | 6.9 ± 1.9 |
| Pain, Week 1 | 6.9 ± 1.9 |
| Pain, Week 12 | 3.6 ± 2.4 |
| Pain, Week 24 | 3.0 ± 2.2 |
| Activity (participant), Screening | 6.6 ± 2.3 |
| Activity (participant), Week 1 | 5.9 ± 2.5 |
| Activity (participant), Week 12 | 4.7 ± 2.8 |
| Activity (participant), Week 24 | 3.9 ± 2.7 |
| Activity (investigator), Screening | 6.4 ± 2.0 |
| Activity (investigator), Week 1 | 6.3 ± 2.1 |
| Activity (investigator), Week 12 | 3.9 ± 3.9 |
| Activity (investigator), Week 24 | 3.0 ± 2.5 |
The efficacy of rituximab was assessed by evaluating inflamed joints.
| number of inflamed joints | Rituximab |
|---|---|
| Inflamed joints, Screening | 17.5 ± 8.6 |
| Inflamed joints, EOT | 3.8 ± 4.9 |
| Inflamed joints, EOFU | 4.4 ± 5.7 |
Collected over Up to Week 48. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 12/232 (5.2%) | 189/232 (81.5%) |
| Event | Rituximab |
|---|---|
| Abdominal distensionGastrointestinal disorders | 1/232 |
| Acute gastroenteritisGastrointestinal disorders | 1/232 |
| Ovarian neoplasm NOSReproductive system and breast disorders | 1/232 |
| Uterine myomaReproductive system and breast disorders | 1/232 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/232 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/232 |
| Tubo-ovarian abscessInfections and infestations | 1/232 |
| Arthritis aggravatedMusculoskeletal and connective tissue disorders | 1/232 |
| Cerebral infarctionNervous system disorders | 1/232 |
| DepressionPsychiatric disorders | 1/232 |
| Event | Rituximab |
|---|---|
| HeadacheNervous system disorders | 40/232 |
| Urinary tract infectionInfections and infestations | 23/232 |
| NauseaGastrointestinal disorders | 22/232 |
| DizzinessNervous system disorders | 17/232 |
| DiarrheaGastrointestinal disorders | 16/232 |
| DyspepsiaGastrointestinal disorders | 15/232 |
| ColdRespiratory, thoracic and mediastinal disorders | 15/232 |
| Upper respiratory tract infection viral NOSInfections and infestations | 14/232 |
| Hypertension arterialVascular disorders | 12/232 |
| VomitingGastrointestinal disorders | 9/232 |
The safety population included all eligible participants who received one treatment dose of rituximab and have completed the follow up period (Week 48) regardless of whether withdrawn or not from the study.
| Age, Continuous(years) | Rituximab |
|---|---|
| Mean | 48.6 ± 12.2 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 207 |
| Male | 25 |
The record gives a start of Feb 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Rituximab